4 TRATAMIENTOS SCLC-ES EN 1.ª LINE EN EUROPA : ATEZOLIZUMAB, DURVALUMAB ,SERPLULIMAB Y TISLELIZUMAB.
LURBINECTEDIN CON IMFORTE TODO EL MUNDO SABE QUE DE APROBARSE NO SERÍA PARA TRATAMIENTO DE PRIMERA LÍNEA .... SINO QUE SERÍA PARA EL MANTENIMIENTO EN EL ENTORNO DE PRIMERA LÍNEA ... O SEA SERÍA UN TRATAMIENTO TRAS LA PRIMERA LÍNEA ... PARA QUE LOS PACIENTES NO SE VAYAN A SEGUNDA LÍNEA .
09 agosto 2009
Bolsas tomadas por maquinas ... ¿ Mafias ? ...
http://jarillabolsa.blogspot.com/2009/08/la-mafia-de-la-bolsa.html
J&J Actualiza el OVA 301 .
PD : J&J actualiza el ensayo OVA 301 y tal y como ya sabiamos consta que el Dossier se elaboro con los Resultdos existentes en fecha Mayo 2008 ... con esos datos el ODAC y la FDA saben que Yondelis Funciona y que alarga la vida a las pacientes ... pero quieren mas datos Finales ... y es ahi en donde estan todas las dudas ... ¿ Sera capaz J&J de Convencer o de tener esos datos que pide la ODAC para antes de la evaluacion de la FDA en Septiembre ? ... de ser asi Bingo ... de No ser asi la FDA nos va a pedir esos datos y meses de por medio ...
Primary Outcome Measures:
*.- Progression-free survival as assessed by independent radiology review [ Time Frame: every 8 weeks after randomization ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
*.- Overall survival [ Time Frame: every 8 weeks for first 2 years then every 3 months thereafter ] [ Designated as safety issue: Yes ]
*.- Response rate [ Time Frame: every 8 weeks ] [ Designated as safety issue: No ]
*.- Safety [ Time Frame: weekly until treatment is terminated ] [ Designated as safety issue: Yes ]
*.- Pharmacokinetics [ Time Frame: weekly during cycle 1 & 2 ] [ Designated as safety issue: No ]
Study Start Date: April 2005
Estimated Study Completion Date: May 2011
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
...
Primary Outcome Measures:
*.- Progression-free survival as assessed by independent radiology review [ Time Frame: every 8 weeks after randomization ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
*.- Overall survival [ Time Frame: every 8 weeks for first 2 years then every 3 months thereafter ] [ Designated as safety issue: Yes ]
*.- Response rate [ Time Frame: every 8 weeks ] [ Designated as safety issue: No ]
*.- Safety [ Time Frame: weekly until treatment is terminated ] [ Designated as safety issue: Yes ]
*.- Pharmacokinetics [ Time Frame: weekly during cycle 1 & 2 ] [ Designated as safety issue: No ]
Study Start Date: April 2005
Estimated Study Completion Date: May 2011
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
...